On 24th July 2016, the 33rd annual session of National Pharmaceutical Industry Information Association was held in Chongqing, where TOP 100 Enterprises of China Pharmaceutical Industry 2015 were published. It was the second time for YRPG to win the first honor after 2014, meanwhile, it has been the 7th year for us to achieve TOP 3. At the same time YRPG was granted with the title of Best Industrial Enterprise with China Pharmaceutical R&D Production Line.
The list of TOP 100 Enterprises of China Pharmaceutical Industry this year was recognized as Ranking of Pharmaceutical Industry by MIIT. The list manifests the latest layout and setup of Chinese pharmaceutical industry from respects of authority, justice and objectivity. Despite of slow growth of the whole industry, the development of TOP 100 Enterprises is proceeding smoothly. According to the statistics and analyze from China National Pharmaceutical Industry Information Center, in 2015 main business income of TOP 100 enterprises broke through RMB 600 billion for the first time and reached in all 613.1 billion, increasing 5.3% compared to last year. Profitability of these enterprises are apparently higher than integral level of the industry. In 2015, for TOP 100 Enterprises, the annual rate of increase of total profit was 18.7%, while for integral industry, the rate was only 12.5%. There was a substantial increase in the threshold for finalists compared to year 2014, the bottom line was RMB 2.3 billion in 2015.
The winners are always the strongest. Compared with data of 2014, 44 enterprises got their rankings improved in 2015, while 39 enterprises found their rankings fall. 5 new companies turned up. In this year, there were 16 enterprises with assets over RMB 10 billion, the number is 5 more than last year, showing the large increase in industrial concentration.
YRPG stays on the champion position of TOP 100 Enterprises among China pharmaceutical industry, indicating its successful management strategy in all aspects, such as layout of production line, R&D of new drugs, sales & marketing, as well as brand building. YRPG always focuses on innovation, adhering to integrating innovation, quality and brand together to achieve the enterprise transformation and upgrading, so as the leapfrog development. In this March, YRPG was honored with the nomination of China Quality Award-the highest governmental honor in quality field of China. This is another nation level quality award that was owned by YRPG after its acquisition of Jiangsu Quality Award in 2014, indicating that quality management mode and innovation management are highly recognized and affirmed by the nation. Till this July YRPG has held on to the top spot for 12 years with our QC achievements. Last year the Gingko Leaf Extract and Gingko Leaf Tablet passed the EU GMP authentication, thus making YRPG the first domestic manufacturer of Gingko Leaf products to acquire European certification. From 2014 to 2015, YRPG ranked first among China Bio-pharmaceutical fields respectively with brand strength and brand value, becoming No.1 brand among China pharmaceutical enterprises.
At present, Yangtze River is deepening Supply-Side Structural Reform, firmly sticking to the lifeline of quality, and pushing forward industry innovation and upgrading. YRPG spares no efforts to build Longfengtang as the TCM kingdom, arranging the Health Industry. Aiming at uilding another YRPG at the 13th Five Year Plan, YRPG takes the lead in starting the modernization, standardization and internationalization
It has been reported that TOP 100 enterprises of China Pharmaceutical
Industry is the only official document reflecting operational economic
status of national pharmaceutical industry. It consists of 100
enterprises among pharmaceutical industry with the best main business
incomes, the statistical data are based on Annual Report of China Pharmaceutical Statistics published
by MIIT. The TOP 100 Enterprises are the hard core of China
pharmaceutical industry, representing the highest level in this area. (Source: Yangtze River Pharmaceutical Group)
A single purchase
